Actively Recruiting
Exploration of the Metabolic Mechanisms of Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With ADHD
Led by National Taiwan University Hospital · Updated on 2024-03-26
160
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how methylphenidate treatment affects brain activity and metabolism in children with attention-deficit/hyperactivity disorder (ADHD). This study aims to identify biological markers that can predict which children will respond to methylphenidate and to understand the metabolic pathways behind its effects on brain function. The research compares children with ADHD to neurotypical controls to explore differences in brain electrophysiology and metabolism. During the study, children diagnosed with ADHD will receive 12 weeks of methylphenidate treatment. The study includes two groups: children with ADHD meeting specific diagnostic criteria and typically developing children without ADHD. Researchers will measure changes in brain activity and metabolic profiles before and after treatment to identify patterns associated with response to methylphenidate. Participants will undergo a variety of assessments including diagnostic interviews, symptom evaluations, questionnaires, neuropsychological testing, and multiple neurobiological assessments. Laboratory analyses such as liquid chromatography-mass spectrometry will be used to study metabolic changes. The study spans four years, with detailed repeated measures to track treatment effects and understand underlying mechanisms in children aged 6 to 18 years.
CONDITIONS
Brief Title
Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With ADHD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 6 to 18 years who meet DSM-5 criteria for ADHD
- ADHD patients with a Clinical Global Impressions-ADHD-Severity score greater than 4
- ADHD patients with a Full IQ score greater than 80
- Neurotypical participants aged 6 to 18 years with no lifetime psychiatric disorder by DSM-5 criteria
You will not qualify if you...
- Patients with major psychiatric disorders such as autism spectrum disorder, schizophrenia, mood disorders, or substance use disorders
- Patients with major central nervous system disorders like epilepsy
- Patients with major systemic diseases such as diabetes mellitus or cardiovascular diseases
- Patients who have ever taken medication for ADHD symptoms
- Neurotypical participants with central nervous system disorders or major systemic diseases
- Neurotypical participants who have taken psychotropic drugs or have Full IQ scores less than 80
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants with ADHD receive 12-week treatment with methylphenidate while undergoing assessments to explore metabolic and electrophysiological changes.
Visits scheduled throughout the 12-week treatment period for assessments and monitoring
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital
Taipei, Taiwan, 110
Actively Recruiting
Research Team
C
Chi-Yung Shang, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here